e-learning
resources
ERJ
2009
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study
Stolz D., Smyrnios N., Eggimann P., Pargger H., Thakkar N., Siegemund M., Marsch S., Azzola A., Rakic J., Mueller B., Tamm M.
Source:
Eur Respir J 2009; 34: 1364-1375
Journal Issue:
December
Disease area:
Respiratory critical care, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Stolz D., Smyrnios N., Eggimann P., Pargger H., Thakkar N., Siegemund M., Marsch S., Azzola A., Rakic J., Mueller B., Tamm M.. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009; 34: 1364-1375
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Related content which might interest you:
Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia
Source: Eur Respir Rev 2007; 16: 45-49
Year: 2007
Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia
Source: Eur Respir J 2011; 37: 1332-1339
Year: 2011
Antibiotic treatment for nosocomial pneumonia
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211
Year: 2004
Diagnosis and treatment of nosocomial pneumonia in ALI/ARDS patients
Source: Eur Respir J 2003; 22: 77S-83S
Year: 2003
Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)?
Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders
Year: 2015
Ventilator-associated pneumonia due to colistin susceptible-only microorganisms
Source: Eur Respir J 2007; 30: 307-313
Year: 2007
Optimising the duration of antibiotic therapy for ventilator-associated pneumonia
Source: Eur Respir Rev 2007; 16: 40-44
Year: 2007
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010
Aerosolised treatment for VAP
Source: Eur Respir Mon 2011; 53: 54-65
Year: 2011
Impact of guidelines on HAP and VAP outcomes
Source: Eur Respir Mon 2011; 53: 66-73
Year: 2011
Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 33-39
Year: 2007
Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia
Source: Eur Respir J 2008; 31: 356-362
Year: 2008
Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia
Source: Eur Respir J 2009; 33: 153-159
Year: 2009
Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia
Source: Eur Respir J 2008; 32: 726-732
Year: 2008
Predictive value of procalcitonin in ventilator-associated pneumonia
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007
Empiric antimicrobial therapy for ventilator-associated pneumonia after brain injury
Source: Eur Respir J 2016; 47: 1219-1228
Year: 2016
Appropriateness and delay to initiate therapy in ventilator-associated pneumonia
Source: Eur Respir J 2006; 27: 158-164
Year: 2006
Individual monitoring of procalcitonin and C-reactive protein levels as a criterion for cancel of antibiotic therapy in patients with severe community-acquired pneumonia
Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections
Year: 2013
Reducing antibiotics use for ventilator-associated pneumonia in brain-injured patients
Source: Eur Respir J 2016; 47: 1060-1061
Year: 2016
The approach to antibiotic treatment in community-acquired pneumonia
Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept